NO20075268L - Fremgangsmate for fremstilling av opioidmodulatorer - Google Patents

Fremgangsmate for fremstilling av opioidmodulatorer

Info

Publication number
NO20075268L
NO20075268L NO20075268A NO20075268A NO20075268L NO 20075268 L NO20075268 L NO 20075268L NO 20075268 A NO20075268 A NO 20075268A NO 20075268 A NO20075268 A NO 20075268A NO 20075268 L NO20075268 L NO 20075268L
Authority
NO
Norway
Prior art keywords
preparation
opioid modulators
opioid
modulators
agonists
Prior art date
Application number
NO20075268A
Other languages
English (en)
Inventor
Wei He
Chaozhong Cai
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36646011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075268(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20075268L publication Critical patent/NO20075268L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Foreliggende oppfinnelse angår nye fremgangsmåter for fremstilling av opioidmodulatorer (agonister og antagonister) og intermediater ved deres syntese. Opioidmodulatorene er anvendelige for behandling og hindring av smerte og gastrointestinale forstyrrelser.
NO20075268A 2005-03-14 2007-10-15 Fremgangsmate for fremstilling av opioidmodulatorer NO20075268L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66178405P 2005-03-14 2005-03-14
PCT/US2006/008240 WO2006098982A1 (en) 2005-03-14 2006-03-06 Process for the preparation of opioid modulators

Publications (1)

Publication Number Publication Date
NO20075268L true NO20075268L (no) 2007-12-10

Family

ID=36646011

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20075269A NO340604B1 (no) 2005-03-14 2007-10-15 Fremgangsmåte for fremstilling av opioidmodulatorer
NO20075268A NO20075268L (no) 2005-03-14 2007-10-15 Fremgangsmate for fremstilling av opioidmodulatorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20075269A NO340604B1 (no) 2005-03-14 2007-10-15 Fremgangsmåte for fremstilling av opioidmodulatorer

Country Status (30)

Country Link
US (4) US7629488B2 (no)
EP (2) EP1863764A1 (no)
JP (3) JP5384933B2 (no)
KR (2) KR20070112255A (no)
CN (2) CN101175725B (no)
AR (2) AR054745A1 (no)
AU (2) AU2006223394B2 (no)
BR (2) BRPI0607793A2 (no)
CA (2) CA2601481C (no)
CR (1) CR9438A (no)
CY (1) CY1116104T1 (no)
DK (1) DK1858850T3 (no)
EA (2) EA014366B1 (no)
ES (1) ES2535048T3 (no)
HR (1) HRP20150417T1 (no)
HU (1) HUE024912T2 (no)
IL (3) IL185974A0 (no)
ME (1) ME02110B (no)
MX (2) MX2007011412A (no)
MY (1) MY145333A (no)
NI (1) NI200700237A (no)
NO (2) NO340604B1 (no)
NZ (1) NZ590570A (no)
PL (1) PL1858850T3 (no)
PT (1) PT1858850E (no)
RS (1) RS53873B1 (no)
SI (1) SI1858850T1 (no)
TW (3) TW200700388A (no)
WO (2) WO2006099060A2 (no)
ZA (2) ZA200708810B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
KR101166342B1 (ko) * 2004-03-15 2012-07-18 얀센 파마슈티카 엔.브이. 아편계 약물 수용체 조절자로서의 신규의 화합물
ES2535048T3 (es) * 2005-03-14 2015-05-04 Janssen Pharmaceutica Nv Proceso para la preparación de moduladores de opioides
WO2009009480A2 (en) * 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
CN106866463B (zh) * 2017-01-24 2018-08-28 富乐马鸿凯（大连）医药有限公司 艾沙度林中间体的制备方法
US10738013B2 (en) 2017-01-27 2020-08-11 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
US20230312542A1 (en) 2020-03-31 2023-10-05 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法
CN114507252B (zh) * 2022-02-21 2023-10-27 广西大学 新型芳基硅烷化合物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430129A (en) * 1977-08-09 1979-03-06 Mitsubishi Gas Chem Co Inc Preparation of toluic acid amide
JPS5528959A (en) * 1978-08-22 1980-02-29 Sumitomo Chem Co Ltd Production of amide derivative
FR2584401B1 (fr) * 1985-07-04 1987-11-20 Ile De France Nouveau benzamide, son procede de preparation et son application dans le domaine therapeutique
JP2727243B2 (ja) * 1988-12-27 1998-03-11 日本化薬株式会社 ２−アシルアミノ桂皮酸誘導体の製造法
US5684175A (en) * 1993-02-05 1997-11-04 Napro Biotherapeutics, Inc. C-2' hydroxyl-benzyl protected, N-carbamate protected (2R, 3S)- 3-phenylisoserine and production process therefor
JP3493206B2 (ja) * 1993-03-19 2004-02-03 ダイセル化学工業株式会社 光学活性β−アミノ酸類の製法
JP3486922B2 (ja) * 1993-08-23 2004-01-13 住友化学工業株式会社 酸アミドの製造法
MY113488A (en) * 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
JPH09295939A (ja) * 1995-09-26 1997-11-18 Takeda Chem Ind Ltd リン酸アミド誘導体、その製造法および用途
OA11901A (en) * 1998-03-11 2006-04-10 Searle & Co Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors.
DK1055665T3 (da) * 1999-05-28 2004-03-01 Pfizer Prod Inc 3-(3-hydroxyphenyl)-3-aminopropionamidderivater
AU2479702A (en) * 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
KR101166342B1 (ko) * 2004-03-15 2012-07-18 얀센 파마슈티카 엔.브이. 아편계 약물 수용체 조절자로서의 신규의 화합물
ES2535048T3 (es) * 2005-03-14 2015-05-04 Janssen Pharmaceutica Nv Proceso para la preparación de moduladores de opioides

Also Published As

Publication number Publication date
JP2008533141A (ja) 2008-08-21
JP5802242B2 (ja) 2015-10-28
TW200700388A (en) 2007-01-01
EA200701979A1 (ru) 2008-04-28
ZA200708810B (en) 2009-01-28
CA2601481A1 (en) 2006-09-21
EP1858850A2 (en) 2007-11-28
KR20070116067A (ko) 2007-12-06
CN101175725A (zh) 2008-05-07
PT1858850E (pt) 2015-02-24
US20060211863A1 (en) 2006-09-21
KR20070112255A (ko) 2007-11-22
US7629488B2 (en) 2009-12-08
EA014366B1 (ru) 2010-10-29
HRP20150417T1 (xx) 2015-09-25
DK1858850T3 (en) 2015-02-09
IL185972A (en) 2013-07-31
IL185974A0 (en) 2008-01-06
RS53873B1 (sr) 2015-08-31
CN101175726A (zh) 2008-05-07
CR9438A (es) 2008-09-09
SI1858850T1 (sl) 2015-04-30
MY145333A (en) 2012-01-31
EP1863764A1 (en) 2007-12-12
MX2007011409A (es) 2008-02-22
WO2006099060A2 (en) 2006-09-21
IL209402A0 (en) 2011-01-31
TWI414518B (zh) 2013-11-11
AR053170A1 (es) 2007-04-25
PL1858850T3 (pl) 2015-06-30
US20060211861A1 (en) 2006-09-21
JP5384933B2 (ja) 2014-01-08
WO2006099060A3 (en) 2006-11-02
CA2601481C (en) 2013-11-12
US20100036132A1 (en) 2010-02-11
ZA200708809B (en) 2009-03-25
US20100152460A1 (en) 2010-06-17
AU2006223394B2 (en) 2012-10-18
IL185972A0 (en) 2008-01-06
NI200700237A (es) 2008-06-25
IL209402A (en) 2015-06-30
NO340604B1 (no) 2017-05-15
BRPI0607793A2 (pt) 2009-06-13
MX2007011412A (es) 2008-02-22
KR101280929B1 (ko) 2013-07-01
AU2006223394A1 (en) 2006-09-21
BRPI0607792A2 (pt) 2009-06-13
NZ590570A (en) 2012-06-29
AR054745A1 (es) 2007-07-11
EA015512B1 (ru) 2011-08-30
HUE024912T2 (en) 2016-02-29
WO2006098982A1 (en) 2006-09-21
TWI500595B (zh) 2015-09-21
JP2008533143A (ja) 2008-08-21
TW201302676A (zh) 2013-01-16
ME02110B (me) 2015-10-20
EP1858850B1 (en) 2015-01-21
TW200716548A (en) 2007-05-01
CN101175725B (zh) 2011-02-02
CA2601674A1 (en) 2006-09-21
EA200701978A1 (ru) 2008-04-28
ES2535048T3 (es) 2015-05-04
AU2006223482A1 (en) 2006-09-21
CY1116104T1 (el) 2017-02-08
JP2013234192A (ja) 2013-11-21
NO20075269L (no) 2007-12-10

Similar Documents

Publication Publication Date Title
NO20075269L (no) Fremgangsmate for fremstilling av opioidmodulatorer
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
ATE469897T1 (de) Indazolcarbonsäureamidverbindungen
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
TW200745109A (en) Pyrrolo-pyridine kinase modulators
EA201071057A1 (ru) Производные азетидина и циклобутана как ингибиторы jak-киназ
NO20076036L (no) Nye oksadiazolderivater og deres medisinske anvendelse
NO20071272L (no) Modulatorer av muskarine reseptorer.
NO20083011L (no) Modulatorer av muskarine receptorer
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
NO20091415L (no) Fremgangsmate og mellomprodukter for fremstilling av integraseinhibitorer
DK2152690T3 (da) Pyridylpiperidinorexin-receptorantagonister
JO2645B1 (en) Vehicles
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MX2009003981A (es) Agentes moduladores del receptor de calcio.
NO20084006L (no) Modulatorer av muskarinreseptorer
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
NO20090073L (no) 1,3-disubstitue 4-metyl-1H-pyrol-2-karboksamider og deres anvendelse for fremstlling av medikamenter
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
ATE495171T1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
EA201190313A1 (ru) Замещенные пиперидины
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application